Zolbetuximab is under clinical development by Astellas Pharma and currently in Pre-Registration for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Pre-Registration drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Zolbetuximab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zolbetuximab (claudiximab, IMAB-362) is under development for the treatment of advanced adenocarcinoma of the Gastroesophageal Junction, gastric cancer and metastatic pancreatic adenocarcinoma. The drug candidate is administered as an intravenous infusion. It is an Ig1 iMAB acts by targeting splice variant of claudin 18 target (claudin 18.2). It is developed based on ideal monoclonal antibody (IMABS) therapeutics. It was under development for the treatment of solid tumors including ovarian cancer and lung cancer.
For a complete picture of Zolbetuximab’s drug-specific PTSR and LoA scores, buy the report here.